TWI369205B - Sulfonyl amide derivatives for the treatment of abnormal cell growth - Google Patents

Sulfonyl amide derivatives for the treatment of abnormal cell growth

Info

Publication number
TWI369205B
TWI369205B TW097113908A TW97113908A TWI369205B TW I369205 B TWI369205 B TW I369205B TW 097113908 A TW097113908 A TW 097113908A TW 97113908 A TW97113908 A TW 97113908A TW I369205 B TWI369205 B TW I369205B
Authority
TW
Taiwan
Prior art keywords
treatment
cell growth
abnormal cell
amide derivatives
sulfonyl amide
Prior art date
Application number
TW097113908A
Other languages
English (en)
Chinese (zh)
Other versions
TW200848050A (en
Inventor
Michael Joseph Luzzio
Christopher Lowell Autry
Samit Kumar Bhattacharya
Kevin Daniel Freeman-Cook
Matthew Merrill Hayward
Catherine Angela Hulford
Kendra Louise Nelson
Jun Xiao
Xumiao Zhao
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TW200848050A publication Critical patent/TW200848050A/zh
Application granted granted Critical
Publication of TWI369205B publication Critical patent/TWI369205B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
TW097113908A 2007-04-18 2008-04-17 Sulfonyl amide derivatives for the treatment of abnormal cell growth TWI369205B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91259707P 2007-04-18 2007-04-18

Publications (2)

Publication Number Publication Date
TW200848050A TW200848050A (en) 2008-12-16
TWI369205B true TWI369205B (en) 2012-08-01

Family

ID=39646361

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097113908A TWI369205B (en) 2007-04-18 2008-04-17 Sulfonyl amide derivatives for the treatment of abnormal cell growth

Country Status (32)

Country Link
US (13) US7928109B2 (enExample)
EP (1) EP2146779B1 (enExample)
JP (1) JP4782239B2 (enExample)
KR (1) KR101132880B1 (enExample)
CN (2) CN101678215B (enExample)
AP (1) AP2009005010A0 (enExample)
AR (1) AR066125A1 (enExample)
AU (1) AU2008240359B2 (enExample)
BR (1) BRPI0810411B8 (enExample)
CA (1) CA2684447C (enExample)
CL (1) CL2008001076A1 (enExample)
CO (1) CO6260093A2 (enExample)
CU (1) CU23813A3 (enExample)
DK (1) DK2146779T3 (enExample)
DO (1) DOP2009000248A (enExample)
EA (1) EA016679B1 (enExample)
EC (1) ECSP099694A (enExample)
ES (1) ES2593486T3 (enExample)
GE (1) GEP20125581B (enExample)
GT (1) GT200900272A (enExample)
IL (3) IL201468A (enExample)
MA (1) MA31319B1 (enExample)
MX (1) MX2009011090A (enExample)
NI (1) NI200900190A (enExample)
NZ (1) NZ580372A (enExample)
PA (1) PA8777101A1 (enExample)
PE (1) PE20090434A1 (enExample)
TN (1) TN2009000428A1 (enExample)
TW (1) TWI369205B (enExample)
UA (1) UA97834C2 (enExample)
UY (1) UY31026A1 (enExample)
WO (1) WO2008129380A1 (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101678215B (zh) * 2007-04-18 2014-10-01 čū‰į‘žäš§å“å…Žåļ į”Ļ䚎æēŧį–—åž‚åļļįŧ†čƒžį”Ÿé•ŋįš„įĢšé…°čƒščĄį”Ÿį‰Đ
US8372974B2 (en) * 2008-03-20 2013-02-12 Boehringer Ingelheim International Gmbh Regioselective preparation of substituted pyrimidines
UY31714A (es) * 2008-03-20 2009-11-10 Boehringer Ingelheim Int PreparaciÃģn selectiva de pirimidinas sustituidas
US20100056524A1 (en) * 2008-04-02 2010-03-04 Mciver Edward Giles Compound
EA201100436A1 (ru) * 2008-09-03 2011-10-31 БаÐđÐĩŅ€ КŅ€ÐūÐŋŅÐ°ÐđÐĩÐ―Ņ АÐģ ГÐĩŅ‚ÐĩŅ€ÐūŅ†ÐļКÐŧÐļŅ‡ÐĩŅÐšÐļ заОÐĩŅ‰ÐĩÐ―Ð―Ņ‹Ðĩ Ð°Ð―ÐļÐŧÐļÐ―ÐūÐŋÐļŅ€ÐļОÐļÐīÐļÐ―Ņ‹ Ðē КаŅ‡ÐĩŅŅ‚ÐēÐĩ Ņ„ŅƒÐ―ÐģÐļŅ†ÐļÐīÐūÐē
UY32240A (es) * 2008-11-14 2010-06-30 Boeringer Ingelheim Kg Nuevas 2,4-diaminopirimidinas, sus sales farmacÃĐuticamente aceptables, composiciones conteniÃĐndolas y aplicaciones.
JP2010111702A (ja) * 2009-02-16 2010-05-20 Tetsuya Nishio čĪ‡įī į’°åŒ–合į‰Đ、そãŪčĢ―造æģ•ãŠã‚ˆãģį”Ļ途
CN101812016B (zh) * 2009-02-23 2013-01-16 æĩ™æąŸæĩ·įŋ”čŊäļšč‚Ąäŧ―有限兎åļ äļ€į§åˆķåĪ‡äūæ‰˜æ˜”åļƒäļ­é—īä―“-6-į”ē埚įƒŸé…ļ及å…ķé…Ŋįš„æ–đæģ•
EP2261211A1 (en) * 2009-05-20 2010-12-15 UniversitÃĐ de Lille 2 Droit et SantÃĐ 1,4-dihydropyridine derivatives and their uses
TW201100441A (en) * 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
EP2438066A2 (en) 2009-06-05 2012-04-11 Cephalon, Inc. PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
WO2011018517A1 (en) 2009-08-14 2011-02-17 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
EP2542536B1 (en) 2010-03-04 2015-01-21 Cellzome Limited Morpholino substituted urea derivatives as mtor inhibitors
US8927547B2 (en) 2010-05-21 2015-01-06 Noviga Research Ab Pyrimidine derivatives
ES2577829T3 (es) * 2010-06-04 2016-07-19 F. Hoffmann-La Roche Ag Derivados de aminopirimidina como moduladores de la LRRK2
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
EP2646448B1 (en) 2010-11-29 2017-08-30 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
US9174946B2 (en) 2011-02-17 2015-11-03 Cancer Therapeutics Crc Pty Ltd Selective FAK inhibitors
US20130324532A1 (en) 2011-02-17 2013-12-05 Cancer Therapeutics Crc Pty Limited Fak inhibitors
DK2688883T3 (en) 2011-03-24 2016-09-05 Noviga Res Ab pyrimidine
US9139534B2 (en) 2011-04-22 2015-09-22 Signal Pharmaceuticals, Llc Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
EP2736901A1 (en) 2011-07-28 2014-06-04 Cellzome Limited Heterocyclyl pyrimidine analogues as jak inhibitors
RU2564419C1 (ru) * 2011-07-28 2015-09-27 ÐĶÐĩÐŧÐŧŅŒÐ·ÐūО ЛÐļОÐļŅ‚ÐļÐī ГÐĩŅ‚ÐĩŅ€ÐūŅ†ÐļКÐŧÐļŅ‡ÐĩŅÐšÐļÐĩ Ð°Ð―Ð°ÐŧÐūÐģÐļ ÐŋÐļŅ€ÐļОÐļÐīÐļÐ―Ð° Ðē КаŅ‡ÐĩŅŅ‚ÐēÐĩ ÐļÐ―ÐģÐļÐąÐļŅ‚ÐūŅ€ÐūÐē jak
WO2013041652A1 (en) 2011-09-21 2013-03-28 Cellzome Limited Morpholino substituted urea or carbamate derivatives as mtor inhibitors
KR20140084130A (ko) 2011-10-07 2014-07-04 ė…€ėĒ€ ëĶŽëŊļ티드 Mtor ė–ĩė œė œëĄœė„œė˜ ëŠĻëĨīíīëĶŽë…ļ ėđ˜í™˜ëœ 바ėīė‚ŽėīíīëĶ­ 픾ëĶŽëŊļ딘 ėš°ë ˆė•„ 또는 ėđīëĨī바ëДėīíŠļ ėœ ë„ėēī
CN104169272A (zh) 2011-12-23 2014-11-26 čĩ›å°”ä―å§†æœ‰é™å…Žåļ ä―œäļšæŋ€é…ķ抑åˆķ剂įš„嘧å•ķ-2,4-乌胹衍į”Ÿį‰Đ
RS54689B1 (sr) * 2012-03-06 2016-08-31 Cephalon, Inc. Spojeni biciklični 2,4- diaminopirimidin derivat kao dualni alk i fak inhibitor
BR112014029310A2 (pt) 2012-05-24 2018-06-26 Cellzome Ltd anÃĄlogos da pirimidina heterocíclica como inibidores da tyk2
EP3091981B1 (en) * 2014-01-09 2021-03-10 Verastem, Inc. Compositions and methods for treatment of abnormal cell growth
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
WO2015120289A1 (en) 2014-02-07 2015-08-13 Verastem, Inc. Methods and compositions for treating abnormal cell growth
KR20170002623A (ko) 2014-05-14 2017-01-06 화ėīėž ėļė―”폎레ėī티드 픾띾ėĄļ로픾ëĶŽë”˜ 및 픾띾ėĄļ로픾ëĶŽëŊļ딘
US9513297B2 (en) 2014-12-16 2016-12-06 Signal Pharmaceuticals, Llc Methods for measurement of inhibition of c-Jun N-terminal kinase in skin
CN107108524A (zh) 2014-12-16 2017-08-29 čĨŋæ žčŊščŊ品有限兎åļ 2‑(叔äļåŸšæ°Ļ埚)‑4‑((1r,3r,4r)‑3‑įūŸåŸšâ€‘4‑į”ē埚įŽŊå·ąåŸšæ°Ļ埚)‑嘧å•ķ‑5‑į”ē酰胹įš„配åˆķį‰Đ
WO2016100452A2 (en) * 2014-12-17 2016-06-23 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP3250557B1 (en) 2015-01-29 2024-11-20 Signal Pharmaceuticals, LLC Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
US10532056B2 (en) * 2015-06-29 2020-01-14 Verastem, Inc. Therapeutic compositions, combinations, and methods of use
CN107922287B (zh) 2015-07-24 2021-04-09 įŧ†čƒžåŸšå› å…Žåļ 合成(1r,2r,5r)-5-æ°Ļ埚-2-į”ē埚įŽŊå·ąé†‡į›é…ļį›įš„æ–đæģ•å’Œå…ķäļ­åŊį”Ļįš„äļ­é—īä―“
CN105153150B (zh) * 2015-08-14 2016-09-14 åĪĐæīĨ小新åŒŧčŊį§‘技有限兎åļ äļ€įąŧåĄå•ķį›įąŧjak抑åˆķ剂、åˆķåĪ‡æ–đæģ•åŠå…ķį”Ļ途
CN105111204B (zh) * 2015-08-14 2016-09-14 åĪĐæīĨ小新åŒŧčŊį§‘技有限兎åļ åĄå•ķį›įąŧ酩æ°Ļé…ļæŋ€é…ķ抑åˆķ剂、åˆķåĪ‡æ–đæģ•åŠå…ķį”Ļ途
CN105503860B (zh) * 2015-10-13 2017-03-01 åĪĐæīĨ小新åŒŧčŊį§‘技有限兎åļ äļ€įąŧč…ˆåŸšå–äŧĢįš„åĄå•ķį›įąŧjak抑åˆķ剂、åˆķåĪ‡æ–đæģ•åŠå…ķį”Ļ途
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
CN106279011A (zh) * 2016-08-16 2017-01-04 æˆéƒ―į™ū之å…īį§‘技åŪžäļšæœ‰é™å…Žåļ äļ€į§2,4‑乌įūŸåŸšâ€‘6‑į”ē埚įƒŸé…ļäđ™é…Ŋįš„åˆķåĪ‡æ–đæģ•
WO2019117813A1 (en) * 2017-12-15 2019-06-20 National University Of Singapore Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis
US20210030703A1 (en) 2018-03-12 2021-02-04 INSERM (Institut National de la SantÃĐ et de la Recherche MÃĐdicale) Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
CN110452229B (zh) * 2018-05-07 2020-11-27 æˆéƒ―æĩ·åˆ›čŊäļšæœ‰é™å…Žåļ 氘äŧĢDefactinib化合į‰Đ及å…ķį”Ļ途
WO2020006724A1 (zh) * 2018-07-05 2020-01-09 æļ…华åĪ§å­Ķ äļ€į§éķ向降č§Ģfak蛋į™―įš„化合į‰Đ及å…ķåš”į”Ļ
EP3856190A4 (en) * 2018-09-27 2022-09-21 Dana Farber Cancer Institute, Inc. DEGRADATION OF FAK OR FAK AND ALK BY CONJUGATION OF FAK AND ALK INHIBITORS WITH E3-LIGASE LIGANDS AND METHODS OF USE
KR102709127B1 (ko) * 2018-12-27 2024-09-24 하ėīë…ļ바 파마ėŠˆí‹°ėŧŽėŠĪ ėļė―”폎레ėī티드 Fak ė–ĩė œė œ 및 ę·ļ ė•―뎞 ėĄ°í•Đ뎞
JP2022547358A (ja) 2019-09-13 2022-11-14 ã‚ļ ã‚Īãƒģã‚đテã‚ĢテãƒĨマト りブ キãƒĢãƒģã‚ĩマ ナã‚ĩマチロã‚ĪãƒĪãƒŦ キãƒĢãƒģã‚ĩマ ホã‚đピã‚ŋãƒŦ æēŧį™‚įĩ„成į‰Đ、įĩ„ãŋ合わせ、及ãģä―ŋį”Ļæ–đæģ•
IL296025A (en) * 2020-03-02 2022-10-01 Sironax Ltd Proptosis inhibitors - diarylamine para-acetamides
EP4251613A4 (en) * 2020-11-27 2024-11-20 Allorion Therapeutics Inc. AMINOHETEROARYL KINASE INHIBITORS
CN112592318B (zh) * 2020-12-12 2022-05-03 čīĩ州åŒŧį§‘åĪ§å­Ķ 2-(4-į”ēæ°Ļ酰埚)č‹ŊčƒšåŸš-4-æ°Ļ埚嘧å•ķ衍į”Ÿį‰Đ及嚔į”Ļ
CN112624966B (zh) * 2020-12-25 2022-12-23 杭州æūģčĩ›čŊšį”Ÿį‰Đį§‘技有限兎åļ äļ€į§2-æ°Ļį”ē埚-4-į”ē埚-5-åĄå•ķįū§é…ļįš„合成æ–đæģ•
US20240059678A1 (en) * 2021-01-18 2024-02-22 Hinova Pharmaceuticals Inc. Synthesis Method for Aminopyrimidine FAK Inhibitor Compound
CN113372334B (zh) * 2021-05-25 2022-05-03 čīĩ州åŒŧį§‘åĪ§å­Ķ 2-(4-į”ēæ°Ļ酰埚)č‹ŊčƒšåŸš-4-æ°Ļ埚-5-äļ‰æ°Ÿį”ē埚嘧å•ķ衍į”Ÿį‰Đ及å…ķåš”į”Ļ
JP2024519388A (ja) * 2021-05-25 2024-05-10 ヒノバ ãƒ•ã‚Ąãƒžãƒžã‚·ãƒĨマテã‚Ģã‚ŦãƒŦã‚š ã‚Īãƒģã‚ģマポノã‚Īテッド į™Œã‚’æēŧį™‚するためãŪåŒŧ薮įĩ„成į‰Đ及ãģそãŪä―ŋį”Ļ
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
CN114716385B (zh) * 2022-04-08 2024-03-12 北䚎åļˆčŒƒåĪ§å­Ķ éķ向įē˜į€æ–‘æŋ€é…ķįš„化合į‰Đ及åˆķåĪ‡æ–đæģ•å’Œåš”į”Ļ
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
JPWO2024071371A1 (enExample) * 2022-09-30 2024-04-04
WO2024249831A2 (en) * 2023-06-02 2024-12-05 Unogen Biotech Ltd. Triple kinase inhibitors
CN117105916B (zh) * 2023-10-23 2024-01-16 åļŒæ žį”Ÿį§‘ïžˆæ·ąåœģ有限兎åļ č‹Ŋåđķ呋喃įąŧ化合į‰Đ及å…ķåŒŧčŊį”Ļ途
WO2025166124A1 (en) * 2024-02-02 2025-08-07 Deciphera Pharmaceuticals, Llc Ulk inhibitors and methods of use thereof
WO2025166180A1 (en) * 2024-02-02 2025-08-07 Deciphera Pharmaceuticals, Llc Ulk inhibitors and methods of use thereof
WO2025199379A1 (en) 2024-03-22 2025-09-25 Bristol-Myers Squibb Company Novel fak degrader compounds and uses thereof

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507146A (en) 1982-12-28 1985-03-26 Ciba-Geigy Corporation 2,4-Diamino-6-halo-5-trifluoromethylpyrimidines having herbicidal activity
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
SG64322A1 (en) 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
WO1995010506A1 (en) 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
ES2153031T4 (es) 1995-04-20 2001-05-16 Pfizer Derivados del acido arilsulfonil hidroxamico como inhibidores de mmp y tnf.
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
EA199900021A1 (ru) 1996-07-13 1999-08-26 ГÐŧаКŅÐū, ГŅ€ŅƒÐŋ ЛÐļОÐļŅ‚ÐĩÐī БÐļŅ†ÐļКÐŧÐļŅ‡ÐĩŅÐšÐļÐĩ ÐģÐĩŅ‚ÐĩŅ€ÐūаŅ€ÐūОаŅ‚ÐļŅ‡ÐĩŅÐšÐļÐĩ ŅÐūÐĩÐīÐļÐ―ÐĩÐ―ÐļŅ Ðē КаŅ‡ÐĩŅŅ‚ÐēÐĩ ÐļÐ―ÐģÐļÐąÐļŅ‚ÐūŅ€ÐūÐē ÐŋŅ€ÐūŅ‚ÐĩÐļÐ―Ņ‚ÐļŅ€ÐūзÐļÐ―ÐšÐļÐ―Ð°Ð·Ņ‹
KR20000067904A (ko) 1996-07-18 2000-11-25 디. ė œėī. ėš°ë“œ, ėŠĪ픾ęē” ė•Œë Œ ė œėī ë§ĪíŠļëĶ­ėŠĪ ëД탈로프로테ė•„ė œė˜ 폎ėŠĪ픾ë„ĪėīíŠļęģ„ ė–ĩė œė œ
KR20000068248A (ko) 1996-08-23 2000-11-25 디. ė œėī. ėš°ë“œ, ėŠĪ픾ęē” ė•Œë Œ ė œėī ė•„ëĶīė„Ī폮닐ė•„ëŊļë…ļ 하ėī드록ė‚žė‚° ėœ ë„ėēī
JP3338064B2 (ja) 1997-01-06 2002-10-28 ãƒ•ã‚Ąã‚Īã‚ķマãƒŧã‚Īãƒģã‚Ŋ į’°įŠķã‚đãƒŦホãƒģčŠ˜å°Žä―“
NZ336840A (en) 1997-02-03 2001-01-26 Pfizer Prod Inc Arylsulfonylamino hydroxamic acid derivatives useful in the treatment of tumor necrosis factor and matrix metalloproteinase mediated diseases
JP2000507975A (ja) 1997-02-07 2000-06-27 ãƒ•ã‚Ąã‚Īã‚ķマãƒŧã‚Īãƒģã‚Ŋ ïžŪ−ヒドロキシ−Îē−ã‚đãƒŦホニãƒŦプロピりãƒģã‚ĒãƒŸãƒ‰čŠ˜å°Žä―“éĄžåŠãģそれらãŪマトナッã‚Ŋã‚đãƒĄã‚ŋロプロテã‚Īナマゞé˜ŧåŪģ薮ãĻしãĶãŪä―ŋį”Ļ
EP0960098A1 (en) 1997-02-11 1999-12-01 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
CA2299355C (en) 1997-08-08 2005-09-27 Pfizer Products Inc. Aryloxyarylsulfonylamino hydroxamic acid derivatives
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
EA200000840A1 (ru) 1998-02-17 2001-02-26 ÐĒŅƒÐŧаŅ€ÐļК, Ð˜Ð―Ðš. ÐÐ―Ņ‚ÐļÐēÐļŅ€ŅƒŅÐ―Ņ‹Ðĩ ÐŋŅ€ÐūÐļзÐēÐūÐīÐ―Ņ‹Ðĩ ÐŋÐļŅ€ÐļОÐļÐīÐļÐ―Ð°
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
IT1302431B1 (it) * 1998-08-12 2000-09-05 Alasi Di Arcieri Franco & C S Dispositivo di controllo di accessi in rete tramite il riconoscimentoveloce di trame applicative che soddisfano un insieme di regole
EP1004578B1 (en) 1998-11-05 2004-02-25 Pfizer Products Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
CA2349832A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
EP1081137A1 (en) 1999-08-12 2001-03-07 Pfizer Products Inc. Selective inhibitors of aggrecanase in osteoarthritis treatment
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US6525051B2 (en) 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
AU783981C (en) 2000-05-08 2007-05-03 Janssen Pharmaceutica N.V. HIV replication inhibitors
AU782948B2 (en) 2000-05-08 2005-09-15 Janssen Pharmaceutica N.V. Prodrugs of HIV replication inhibiting pyrimidines
US6630469B2 (en) 2000-05-09 2003-10-07 Bristol-Myers Squibb Company 5-HT7 receptor antagonists
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
US6853233B1 (en) * 2000-09-13 2005-02-08 Infineon Technologies Ag Level-shifting circuitry having “high” output impedance during disable mode
IT1319686B1 (it) 2000-12-12 2003-10-23 C D Farmasint S R L Procedimento di preparazione di citalopram.
US6989385B2 (en) 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
BR0209774A (pt) 2001-05-29 2004-06-01 Schering Ag Pirimidinas inibidoras de cdk, sua preparaçÃĢo e aplicaçÃĢo como medicamento
CA2450934A1 (en) * 2001-06-19 2002-12-27 Marco Dodier Pyrimidine inhibitors of phosphodiesterase (pde) 7
US20040171630A1 (en) 2001-06-19 2004-09-02 Yuntae Kim Tyrosine kinase inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv Ų…ØīØŠŲ‚ا؊ ØĻØąŲ…ŲŠØŊŲŠŲ†Ø§ØŠ Ų…ØŦØĻØ·ØĐ ŲŲŠØąŲˆØģ اŲ„اŲŠØŊØē
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2003040141A1 (en) 2001-09-28 2003-05-15 Bayer Pharmaceuticals Corporation Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
ATE407678T1 (de) 2001-10-17 2008-09-15 Boehringer Ingelheim Pharma Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7008378B2 (en) * 2002-03-07 2006-03-07 Dean Melanie A Patient conditional diagnosis assessment and symptom tracking system
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003095448A1 (en) * 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
EP1518855B1 (en) 2002-06-28 2011-10-26 Astellas Pharma Inc. Diaminopyrimidinecarboxa mide derivative
HRP20050089B1 (hr) 2002-07-29 2015-06-19 Rigel Pharmaceuticals Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeÃĪśenje ili sprjeÃĪśavanje autoimunosne bolesti
CA2503715A1 (en) 2002-10-30 2004-05-21 Merck & Co., Inc. Kinase inhibitors
JP2006508997A (ja) * 2002-11-28 2006-03-16 シã‚Ļマナãƒģグ ã‚Ēã‚Ŋチã‚Ļãƒģã‚ēã‚žãƒŦシãƒĢフト ïžĢï―ˆï―‹âˆ’ã€ïž°ï―„ï―‹âˆ’ãŠã‚ˆãģïžĄï―‹ï―”âˆ’é˜ŧåŪģ性ピナミã‚ļãƒģ、それらãŪčĢ―造およãģ薮å‰ĪãĻしãĶãŪä―ŋį”Ļ
US7109337B2 (en) * 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
SE0203820D0 (sv) * 2002-12-20 2002-12-20 Astrazeneca Ab chemical compounds
CA2529611C (en) * 2002-12-20 2009-12-15 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
BRPI0407329A (pt) 2003-02-07 2006-01-10 Janssen Pharmaceutica Nv Derivados de pirimidina para a prevençÃĢo de infecçÃĢo de hiv
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
WO2005003103A2 (en) 2003-06-30 2005-01-13 Astrazeneca Ab 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases
WO2005009980A1 (en) 2003-07-22 2005-02-03 Neurogen Corporation Substituted pyridin-2-ylamine analogues
PT1660458E (pt) 2003-08-15 2012-04-27 Novartis Ag 2,4-pirimidinodiaminas Úteis no tratamento de doenças neoplÃĄsicas, desordens inflamatÃģrias e do sistema imunitÃĄrio
WO2005023780A1 (en) 2003-09-05 2005-03-17 Pfizer Products Inc. Selective synthesis of cf3-substituted pyrimidines
US7363505B2 (en) * 2003-12-03 2008-04-22 Pen-One Inc Security authentication method and system
MXPA06011658A (es) 2004-05-14 2006-12-14 Pfizer Prod Inc Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
JP2007537230A (ja) * 2004-05-14 2007-12-20 ãƒ•ã‚Ąã‚Īã‚ķマãƒŧプロダã‚Ŋツãƒŧã‚Īãƒģã‚Ŋ į•°åļļįī°čƒžåĒ—æŪ–ãŪå‡Ķį―Ūį”ĻãŪピナミã‚ļãƒģčŠ˜å°Žä―“
BRPI0511138A (pt) * 2004-05-14 2007-11-27 Pfizer Prod Inc derivados de pirimidina para o tratamento de desenvolvimento celular anormal
JP2007537238A (ja) 2004-05-14 2007-12-20 ãƒ•ã‚Ąã‚Īã‚ķマãƒŧプロダã‚Ŋツãƒŧã‚Īãƒģã‚Ŋ į•°åļļįī°čƒžåĒ—æŪ–ãŪæēŧį™‚ãŪためãŪピナミã‚ļãƒģčŠ˜å°Žä―“
EP1598343A1 (de) 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
PL1756084T3 (pl) 2004-06-04 2009-06-30 Arena Pharm Inc Podstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu oraz profilaktyka i leczenie zaburzeń z metabolizmem związanych
WO2006007532A2 (en) 2004-07-01 2006-01-19 Synta Pharmaceuticals Corp. 2-substituted heteroaryl compounds
US7521457B2 (en) * 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
JP2008515986A (ja) 2004-10-13 2008-05-15 ãƒŊã‚Īã‚đ ïžŪ−ベãƒģã‚žãƒģã‚đãƒŦホニãƒŦį―Ū換ã‚Ēニナノ−ピナミã‚ļãƒģ類侾į‰Đ
TW200628463A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp Heteroaryl compounds
US7923557B2 (en) 2004-11-10 2011-04-12 Synta Pharmaceuticals Corporation Process for preparing trisubstituted pyrimidine compounds
CA2618218C (en) 2005-07-21 2015-06-30 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
WO2007063384A2 (en) * 2005-12-01 2007-06-07 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
CA2634646C (en) * 2005-12-21 2012-04-10 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
CN101678215B (zh) * 2007-04-18 2014-10-01 čū‰į‘žäš§å“å…Žåļ į”Ļ䚎æēŧį–—åž‚åļļįŧ†čƒžį”Ÿé•ŋįš„įĢšé…°čƒščĄį”Ÿį‰Đ

Also Published As

Publication number Publication date
EA200901250A1 (ru) 2010-04-30
US8247411B2 (en) 2012-08-21
WO2008129380A1 (en) 2008-10-30
US20160130250A1 (en) 2016-05-12
EA016679B1 (ru) 2012-06-29
US20170001981A1 (en) 2017-01-05
CN103951658A (zh) 2014-07-30
ES2593486T3 (es) 2016-12-09
US20190047979A1 (en) 2019-02-14
TW200848050A (en) 2008-12-16
IL232511A0 (en) 2014-06-30
CU23813A3 (es) 2012-06-21
CN101678215A (zh) 2010-03-24
IL260560B (en) 2021-04-29
BRPI0810411B8 (pt) 2021-05-25
EP2146779B1 (en) 2016-08-10
US20200002310A1 (en) 2020-01-02
JP2010524914A (ja) 2010-07-22
PE20090434A1 (es) 2009-04-13
US20140100368A1 (en) 2014-04-10
GT200900272A (es) 2010-05-17
GEP20125581B (en) 2012-07-25
MX2009011090A (es) 2009-11-02
US20150080368A1 (en) 2015-03-19
CO6260093A2 (es) 2011-03-22
CN101678215B (zh) 2014-10-01
ECSP099694A (es) 2009-11-30
IL201468A (en) 2014-06-30
IL232511B (en) 2018-07-31
CU20090175A7 (es) 2011-09-21
US20130005964A1 (en) 2013-01-03
UY31026A1 (es) 2008-11-28
AP2009005010A0 (en) 2009-10-31
US20110166120A1 (en) 2011-07-07
KR20090130248A (ko) 2009-12-21
HK1136985A1 (en) 2010-07-16
AU2008240359A1 (en) 2008-10-30
CA2684447C (en) 2012-01-24
BRPI0810411A2 (pt) 2014-10-14
US10450297B2 (en) 2019-10-22
US20240109862A1 (en) 2024-04-04
JP4782239B2 (ja) 2011-09-28
KR101132880B1 (ko) 2012-06-28
EP2146779A1 (en) 2010-01-27
IL201468A0 (en) 2010-05-31
DK2146779T3 (en) 2016-11-28
HK1200450A1 (en) 2015-08-07
US20220251066A1 (en) 2022-08-11
CN103951658B (zh) 2017-10-13
TN2009000428A1 (fr) 2011-03-31
US20170327485A1 (en) 2017-11-16
US8440822B2 (en) 2013-05-14
BRPI0810411B1 (pt) 2019-09-10
UA97834C2 (ru) 2012-03-26
MA31319B1 (fr) 2010-04-01
US20090054395A1 (en) 2009-02-26
CL2008001076A1 (es) 2008-10-24
CA2684447A1 (en) 2008-10-30
AR066125A1 (es) 2009-07-22
AU2008240359B2 (en) 2014-06-26
NI200900190A (es) 2010-01-27
PA8777101A1 (es) 2008-11-19
US7928109B2 (en) 2011-04-19
US20250214963A1 (en) 2025-07-03
DOP2009000248A (es) 2009-11-15
NZ580372A (en) 2012-01-12

Similar Documents

Publication Publication Date Title
TWI369205B (en) Sulfonyl amide derivatives for the treatment of abnormal cell growth
IL191555A0 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
ZA201000022B (en) Novel amide derivative for inhibiting the growth of cancer cells
ZA201002696B (en) Methods of maintaining or increasing growth or cognitive development
IL191471A0 (en) Method of treating abnormal cell growth
PL2209900T3 (pl) Zastosowanie bakterii do wytwarzania bioenergii
ZA201202613B (en) Spiro-condensed cyclohexane derivatives as hsl inhibitors useful for the treatment of diabetes
PL2225238T3 (pl) Pochodne amidÃģw kwasu 6,7-dihydro-5H-imidazo[1,2-a]imidazolo-3-karboksylowego
IL207397A0 (en) Difluorobiphenylamide derivtives for the treatment of ocular hypertension
ZA201006827B (en) Carboxamide-heteroaryl derivatives for the treatment of diabetes
IL178828A0 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
ZA200804777B (en) Method of treating abnormal cell growth
IL199639A0 (en) Improvement of cell growth
EP2225559B8 (en) Assessment of physiological conditions
ZA201101174B (en) 1-amino-alkylcyclohexane derivatives for the treatment of cognitive impairment in tinnitus
ZA201000578B (en) Salts of perindopril
IL202506A0 (en) Neramexane for the treatment of nystagmus
ZA200803526B (en) Process for stabilization of bacterial cells
TH0801001913A (th) āļšāļĢāļĢāļ”āļēāļ­āļ™āļļāļžāļąāļ™āļ˜āđŒāļ‹āļąāļĨāđ‚āļŸāļ™āļīāļĨ āđ€āļ­āđ„āļĄāļ”āđŒ (Sulfonyl amide derivatives) āļŠāļģāļŦāļĢāļąāļšāļāļēāļĢāļĢāļąāļāļĐāļēāļāļēāļĢāđ€āļˆāļĢāļīāļāđ€āļ•āļīāļšāđ‚āļ•āļ‚āļ­āļ‡āđ€āļ‹āļĨāļĨāđŒāļœāļīāļ”āļ›āļāļ•āļī
GB0603773D0 (en) Surgical electrode
GB0715257D0 (en) Phenylthiazolylpiperazine derivatives for the treatment of nuero degenerative diseases
HK1166780A (en) Derivatives of n-acyl-n'-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes
IL207753A0 (en) Substituted 4-aminocyclohexane derivatives for the treatment of pain
GB0516085D0 (en) Treatment of viable cells
GB0710059D0 (en) New morphology of pharmaceutical crystalline form